Literature DB >> 22488668

Optical fiber-based in vivo quantification of growth factor receptors.

Thommey P Thomas1, Yu-Chung Chang, Jing Yong Ye, Alina Kotlyar, Zhengyi Cao, Rameshwer Shukla, Suyang Qin, Theodore B Norris, James R Baker.   

Abstract

BACKGROUND: Growth factor receptors such as epidermal growth factor receptor 1 and human epidermal growth receptor 2 (HER2) are overexpressed in certain cancer cells. Antibodies against these receptors (eg. cetuximab and transtuzumab [Herceptin]) have shown therapeutic value in cancer treatment. The existing methods for the quantification of these receptors in tumors involve immunohistochemistry or DNA quantification, both in extracted tissue samples. The goal of the study was to evaluate whether an optical fiber-based technique can be used to quantify the expression of multiple growth factor receptors simultaneously.
METHODS: The authors examined HER2 expression using the monoclonal antibody trastuzumab as a targeting ligand to test their system. They conjugated trastuzumab to 2 different Alexa Fluor dyes with different excitation and emission wavelengths. Two of the dye conjugates were subsequently injected intravenously into mice bearing HER2-expressing subcutaneous tumors. An optical fiber was then inserted into the tumor through a 30-gauge needle, and using a single laser beam as the excitation source, the fluorescence emitted by the 2 conjugates was identified and quantified by 2-photon optical fiber fluorescence.
RESULTS: The 2 conjugates bound to the HER2-expressing tumor competitively in a receptor-specific fashion, but they failed to bind to a similar cell tumor that did not express HER2. The concentration of the conjugate present in the tumor as determined by 2-photon optical fiber fluorescence was shown to serve as an index of the HER2 expression levels.
CONCLUSIONS: These studies offer a minimally invasive technique for the quantification of tumor receptors simultaneously.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22488668      PMCID: PMC3324314          DOI: 10.1002/cncr.26487

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  55 in total

Review 1.  Current status of HER2 testing: caught between a rock and a hard place.

Authors:  S J Schnitt; T W Jacobs
Journal:  Am J Clin Pathol       Date:  2001-12       Impact factor: 2.493

2.  Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis.

Authors:  Thorsten Maass; Florian R Thieringer; Amrit Mann; Thomas Longerich; Peter Schirmacher; Dennis Strand; Torsten Hansen; Peter R Galle; Andreas Teufel; Stephan Kanzler
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

3.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

4.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

Authors:  G Pauletti; S Dandekar; H Rong; L Ramos; H Peng; R Seshadri; D J Slamon
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

5.  Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.

Authors:  T W Jacobs; A M Gown; H Yaziji; M J Barnes; S J Schnitt
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

6.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  Soonmyung Paik; John Bryant; Elizabeth Tan-Chiu; Edward Romond; William Hiller; Kyeongmee Park; Ann Brown; Greg Yothers; Steve Anderson; Roy Smith; D Lawrence Wickerham; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

7.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.

Authors:  Patrick C Roche; Vera J Suman; Robert B Jenkins; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Ferdinand K Addo; Bronagh Murphy; James N Ingle; Edith A Perez
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

8.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

9.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

Review 10.  Growth factor receptors in breast cancer: potential for therapeutic intervention.

Authors:  Rita Nahta; Gabriel N Hortobágyi; Francisco J Esteva
Journal:  Oncologist       Date:  2003
View more
  1 in total

1.  Real time in vivo investigation of superoxide dynamics in zebrafish liver using a single-fiber fluorescent probe.

Authors:  Yu-Chung Chang; Chuian-Fu Ken; Che-Wei Hsu; Ya-Ging Liu
Journal:  Biomed Opt Express       Date:  2013-08-21       Impact factor: 3.732

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.